G L O B A L B R I E F I N G R E P O RT R E V I E W UNIFY B R A N D E D S T O RY
The World’s First Open Platform for Entrepreneurial Researchers “UNIFY” Opens in 5th May 2020 UNIFY Platform AG is established in Zug, Switzerland in December 2019 by the support of Swiss business hub office for attracting foreign companies at embassy of Switzerland in Japan. They are R&D and management company for UNIFY. UNIFY is a ground breaking global platform that for the first time provides researchers in low and middle income countries with equal opportunities to succeed when compared to excellent health research from high income prestigious academic centers. Based on principles
of connecting e-money, popularity and artificial intelligence linked to well established bibliometric values, the UNIFY platform allows academic research across the world to compete on equal terms, supporting the United Nations Sustainability Development Goals (SDGs). UNIFY works by channeling research incentives to authors of research publications and projects based on their popularity judged by the UNIFY audience using the principles of “throwing money” in combination with bibliometrics and
an accredited credit system. By being sensitive to public demand, research incentives can be aligned with research challenges and research performance by the researchers.
Mr. Atsumi Kaburagi, Co-founder & CTO (CEO of Chemiteras Inc. Japan)
Mr. Takahisa Karita, Co-founder, CFO & COO (Advisory board member of Tsang’s Group UK and Hong Kong)
unify21.com They plan to do the beta closed test of UNIFY before full launch in 11th January 2021. If you join the beta test, please visit below URL. ◆
unify21.com/contact
Management Team
Mr. Tokinori Terada, Founder & CEO (CEO of Chemiteras Inc. Japan)
Dr. Torkel Falkenberg, CRO (Member of the Board of Karolinska Institute, Sweden) GROUPOFNATIONS.COM
112
Mr. Lukas Wadsack, Domicile Director (Partner of Wadsack Zug Switzerland)
Mr. Alan Malcolm, Senior advisor (Head of Asia of Pearson)
Dr. Nigel Clarke, Senior advisor (Chair of the GPhC (General Pharmaceutical Council) UK)
